Squarepoint
AGIO icon

Squarepoint’s Agios Pharmaceuticals AGIO Stock Holding History

Squarepoint’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27,000
Closed -$1.2M – 4979
2024
Q3 		$1.2M Hold
27,000
– – ﹤0.01% 2462
2024
Q2 		$1.16M Buy
+27,000
New +$974K ﹤0.01% 2443

Other funds holding AGIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Squarepoint's AGIO Position: Q1 2026 in Review

Squarepoint increased its Agios Pharmaceuticals (AGIO) stake by 72% in Q1 2026, buying an estimated $2.47M and bringing the position to 208,888 shares worth $7.07M. The position accounts for 0.01% of the portfolio, ranked #1280.

Squarepoint first reported a position in AGIO in Q2 2017 and has held it in 25 quarters since. 232 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Squarepoint held 208,888 shares of Agios Pharmaceuticals worth $7.07M as of Q1 2026.
  • Squarepoint bought 87,125 Agios Pharmaceuticals shares in Q1 2026, an estimated $2.47M.
  • Agios Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q1 2026, its #1280 holding.
  • Squarepoint first reported a position in Agios Pharmaceuticals in Q2 2017 and has held it in 25 quarters since.
  • 232 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.